Objective: Understanding public discourse on emergency use of unproven therapeutics is essential to monitor safe use and combat misinformation. We developed a natural language processing-based pipeline to understand public perceptions of and stances on coronavirus disease 2019 (COVID-19)-related drugs on Twitter across time.

Methods: This retrospective study included 609 189 US-based tweets between January 29, 2020 and November 30, 2021 on 4 drugs that gained wide public attention during the COVID-19 pandemic: (1) Hydroxychloroquine and Ivermectin, drug therapies with anecdotal evidence; and (2) Molnupiravir and Remdesivir, FDA-approved treatment options for eligible patients. Time-trend analysis was used to understand the popularity and related events. Content and demographic analyses were conducted to explore potential rationales of people's stances on each drug.

Results: Time-trend analysis revealed that Hydroxychloroquine and Ivermectin received much more discussion than Molnupiravir and Remdesivir, particularly during COVID-19 surges. Hydroxychloroquine and Ivermectin were highly politicized, related to conspiracy theories, hearsay, celebrity effects, etc. The distribution of stance between the 2 major US political parties was significantly different (P < .001); Republicans were much more likely to support Hydroxychloroquine (+55%) and Ivermectin (+30%) than Democrats. People with healthcare backgrounds tended to oppose Hydroxychloroquine (+7%) more than the general population; in contrast, the general population was more likely to support Ivermectin (+14%).

Conclusion: Our study found that social media users with have different perceptions and stances on off-label versus FDA-authorized drug use across different stages of COVID-19, indicating that health systems, regulatory agencies, and policymakers should design tailored strategies to monitor and reduce misinformation for promoting safe drug use. Our analysis pipeline and stance detection models are made public at https://github.com/ningkko/COVID-drug.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278189PMC
http://dx.doi.org/10.1093/jamia/ocac114DOI Listing

Publication Analysis

Top Keywords

hydroxychloroquine ivermectin
12
understand public
8
public perceptions
8
perceptions stances
8
molnupiravir remdesivir
8
time-trend analysis
8
general population
8
public
5
hydroxychloroquine
5
ivermectin
5

Similar Publications

Rivers at risks: The interplay of "COVID kit" medication misuse and urban waterway contaminants.

Chemosphere

February 2025

Laboratório de Fisiologia de Plantas sob Estresse, Departamento de Botânica, Setor de Ciências Biológicas, Universidade Federal do Paraná, Avenida Coronel Francisco H. dos Santos, 100, Centro Politécnico Jardim das Américas, C. P. 19031, Curitiba, 81531-980, Paraná, Brazil. Electronic address:

This study investigates the environmental impact of the widespread use of "COVID Kit" drugs-azithromycin (AZI), ivermectin (IVE), and hydroxychloroquine (HCQ)-in urban rivers of Curitiba in Brazil, during and after the COVID-19 pandemic. The research focuses on the occurrence and concentrations of these pharmaceuticals in water and sediment samples collected from key urban rivers. Concentrations of AZI, IVE, and HCQ in water ranged from 326 to 3340 ng/L, 130-3340 ng/L, and 304-3314 ng/L, respectively, while in sediment, they ranged from 18 to 249 ng/g, 21-480 ng/g, and 38-673 ng/g, respectively.

View Article and Find Full Text PDF

Background: Understanding how individuals obtain medical information, especially amid changing guidance, is important for improving outreach and communication strategies. In particular, during a public health emergency, interest in unsafe or illegitimate medications can delay access to appropriate treatments and foster mistrust in the medical system, which can be detrimental at both individual and population levels. It is thus key to understand factors associated with said interest.

View Article and Find Full Text PDF

Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials.

Biomedicines

September 2024

Laboratory of Molecular Biology and Genetics, Laboratory of Clinical and Molecular Microbiology, LunGuardian Research Group-Epidemiology of Respiratory and Infectious Diseases, São Francisco University, Bragança Paulista 12916-900, SP, Brazil.

During the coronavirus disease (COVID)-19 pandemic several drugs were used to manage the patients mainly those with a severe phenotype. Potential drugs were used off-label and major concerns arose from their applicability to managing the health crisis highlighting the importance of clinical trials. In this context, we described the mechanisms of the three repurposed drugs [Ivermectin-antiparasitic drug, Chloroquine/Hydroxychloroquine-antimalarial drugs, and Azithromycin-antimicrobial drug]; and, based on this description, the study evaluated the clinical efficacy of those drugs published in clinical trials.

View Article and Find Full Text PDF

Background: the spread of SARS-CoV-2 in the population has amplified the effects of health inequalities, particularly in the most vulnerable groups such as immigrants and refugees. An assessment of the intervention to contain the COVID-19 in these population groups was essential to define new strategies for more equitable, inclusive, and effective health policies to on health.

Objectives: to provide a systematic synopsis of the impact of interventions to contain the spread of SARS-CoV-2 in immigrants.

View Article and Find Full Text PDF

Cardiovascular adverse effects of antiviral therapies for COVID-19: Evidence and plausible mechanisms.

Acta Pharmacol Sin

September 2024

Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, 23298-0204, USA.

Article Synopsis
  • - Antiviral drugs have played a vital role in reducing symptoms and improving outcomes for COVID-19, which is caused by the SARS-CoV-2 virus that can harm multiple organs.
  • - Various antivirals, like remdesivir and paxlovid, received emergency use approval, while some older drugs were repurposed; however, they have also shown some adverse effects, particularly on cardiovascular health.
  • - The review highlights the need to understand the cardiovascular risks of these antivirals, discusses possible underlying biological mechanisms, and suggests that future antiviral development, aided by artificial intelligence, could help address these issues.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!